Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Long-Term Investments (2016 - 2025)

UroGen Pharma (URGN) has disclosed Long-Term Investments for 10 consecutive years, with $380000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Investments rose 117.14% year-over-year to $380000.0, compared with a TTM value of $380000.0 through Sep 2025, up 117.14%, and an annual FY2024 reading of $5.0 million, up 11.55% over the prior year.
  • Long-Term Investments was $380000.0 for Q3 2025 at UroGen Pharma, up from $177000.0 in the prior quarter.
  • Across five years, Long-Term Investments topped out at $10.2 million in Q1 2023 and bottomed at $175000.0 in Q2 2024.
  • Average Long-Term Investments over 5 years is $2.0 million, with a median of $224500.0 recorded in 2023.
  • The sharpest move saw Long-Term Investments crashed 99.44% in 2021, then skyrocketed 4458.3% in 2023.
  • Year by year, Long-Term Investments stood at $223000.0 in 2021, then changed by 0.0% to $223000.0 in 2022, then soared by 1918.83% to $4.5 million in 2023, then increased by 11.55% to $5.0 million in 2024, then plummeted by 92.43% to $380000.0 in 2025.
  • Business Quant data shows Long-Term Investments for URGN at $380000.0 in Q3 2025, $177000.0 in Q2 2025, and $4.5 million in Q1 2025.